Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)

Gilead Sciences, Inc. (GILD)

JPMorgan Annual Healthcare Conference Call

January 13, 2025, 02:15 PM ET

Company Participants

Daniel O'Day - Chairman and Chief Executive Officer

Johanna Mercier - Chief Commercial Officer

Stacey Ma - Executive Vice President, Pharmaceutical Development and Manufacturing

Andrew Dickinson - Chief Financial Officer

Flavius Martin - Executive Vice President, Research

Conference Call Participants

Chris Schott - JPMorgan

Presentation

Chris Schott

Good morning, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be introducing Gilead today. From the company, we're going to have a presentation from Dan O'...

SA Transcripts on Seeking Alpha | January 13, 2025

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

The Danish company will be eligible to receive up to $1.7 billion in payments which include an upfront payment of $250 million from Gilead. In return, Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 (signal transducer and activator of transcription 6) program. Targeting STAT6 has shown potential preclinically to treat a broad population of patients with inflammatory conditions such as atopic dermatitis, asthma, and COPD, the statement said.

Yahoo | January 11, 2025

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

FOSTER CITY, Calif. & BALLERUP, Denmark, January 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.

Yahoo | January 11, 2025

Morgan Stanley upgrades Gilead on HIV treatment growth

Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.

Yahoo | January 10, 2025

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

Yahoo | January 9, 2025

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

Galapagos (GLPG) said Wednesday that it plans to split into two entities, with a new company, or Spi

Yahoo | January 8, 2025

Here’s Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD)

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, U.S. and European indices reached all-time highs, fueled by optimism surrounding central bank easing, decreasing inflation, rising hopes for a soft landing, and stimulus […]

Yahoo | January 6, 2025

Gilead Sciences, Inc. (GILD): A Bull Case Theory

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc. (NASDAQ:GILD)’s share was trading at $91.41 as of Jan 3rd. GILD’s forward P/E was 12.11 according to Yahoo Finance. Gilead Sciences (NASDAQ:GILD) is positioned for significant growth, […]

Yahoo | January 6, 2025

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.

Yahoo | January 3, 2025

Five Best: Novels in Letters

1. I doubt Mary Shelley would ever forgive us for thinking Frankenstein was the monster of her novel, instead of the doctor rescued from icy waters on a voyage to the North Pole by one Capt. R. Walton. While Walton slowly fades into the background and yields to this bright young scientist who reanimated human flesh, we the readers are drawn ever more deeply into this incredible tale, which is often credited as the first science-fiction novel. Walton’s act of kindness in the remote waters contrasts with the increasing cruelty of Victor’s creation; by the end, the actions of both are characterized as central to our humanity.

Yahoo | January 3, 2025